Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab

A 69-year-old man with stage III lung squamous cell carcinoma developed immune-related hepatitis following treatment with durvalumab, and was given high-dose corticosteroids and immunosuppressive drugs (mycophenolate mofetil, azathioprine, tacrolimus) but without demonstrating any improvement. Two c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakashima, Koki, Demura, Yoshiki, Oi, Masahiro, Tabata, Mio, Tada, Toshihiko, Shiozaki, Kohei, Akai, Masaya, Ishizuka, Tamotsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759708/
https://www.ncbi.nlm.nih.gov/pubmed/32727989
http://dx.doi.org/10.2169/internalmedicine.5216-20
_version_ 1783627164607840256
author Nakashima, Koki
Demura, Yoshiki
Oi, Masahiro
Tabata, Mio
Tada, Toshihiko
Shiozaki, Kohei
Akai, Masaya
Ishizuka, Tamotsu
author_facet Nakashima, Koki
Demura, Yoshiki
Oi, Masahiro
Tabata, Mio
Tada, Toshihiko
Shiozaki, Kohei
Akai, Masaya
Ishizuka, Tamotsu
author_sort Nakashima, Koki
collection PubMed
description A 69-year-old man with stage III lung squamous cell carcinoma developed immune-related hepatitis following treatment with durvalumab, and was given high-dose corticosteroids and immunosuppressive drugs (mycophenolate mofetil, azathioprine, tacrolimus) but without demonstrating any improvement. Two cycles of infliximab (5 mg/kg) were then administered and thereafter the hepatitis improved. At the time of writing (9 months after the initiation of first course of durvalumab), the patient is alive without either any hepatitis symptoms nor any lung cancer progression. Infliximab may be effective for treating non-small cell lung cancer (NSCLC) patients who develop immunosuppressive drug-resistant immune-related hepatitis caused by durvalumab.
format Online
Article
Text
id pubmed-7759708
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-77597082020-12-31 Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab Nakashima, Koki Demura, Yoshiki Oi, Masahiro Tabata, Mio Tada, Toshihiko Shiozaki, Kohei Akai, Masaya Ishizuka, Tamotsu Intern Med Case Report A 69-year-old man with stage III lung squamous cell carcinoma developed immune-related hepatitis following treatment with durvalumab, and was given high-dose corticosteroids and immunosuppressive drugs (mycophenolate mofetil, azathioprine, tacrolimus) but without demonstrating any improvement. Two cycles of infliximab (5 mg/kg) were then administered and thereafter the hepatitis improved. At the time of writing (9 months after the initiation of first course of durvalumab), the patient is alive without either any hepatitis symptoms nor any lung cancer progression. Infliximab may be effective for treating non-small cell lung cancer (NSCLC) patients who develop immunosuppressive drug-resistant immune-related hepatitis caused by durvalumab. The Japanese Society of Internal Medicine 2020-07-28 2020-12-01 /pmc/articles/PMC7759708/ /pubmed/32727989 http://dx.doi.org/10.2169/internalmedicine.5216-20 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Nakashima, Koki
Demura, Yoshiki
Oi, Masahiro
Tabata, Mio
Tada, Toshihiko
Shiozaki, Kohei
Akai, Masaya
Ishizuka, Tamotsu
Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab
title Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab
title_full Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab
title_fullStr Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab
title_full_unstemmed Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab
title_short Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab
title_sort infliximab was found to be effective for treating immunosuppressive drug-resistant hepatitis due to durvalumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759708/
https://www.ncbi.nlm.nih.gov/pubmed/32727989
http://dx.doi.org/10.2169/internalmedicine.5216-20
work_keys_str_mv AT nakashimakoki infliximabwasfoundtobeeffectivefortreatingimmunosuppressivedrugresistanthepatitisduetodurvalumab
AT demurayoshiki infliximabwasfoundtobeeffectivefortreatingimmunosuppressivedrugresistanthepatitisduetodurvalumab
AT oimasahiro infliximabwasfoundtobeeffectivefortreatingimmunosuppressivedrugresistanthepatitisduetodurvalumab
AT tabatamio infliximabwasfoundtobeeffectivefortreatingimmunosuppressivedrugresistanthepatitisduetodurvalumab
AT tadatoshihiko infliximabwasfoundtobeeffectivefortreatingimmunosuppressivedrugresistanthepatitisduetodurvalumab
AT shiozakikohei infliximabwasfoundtobeeffectivefortreatingimmunosuppressivedrugresistanthepatitisduetodurvalumab
AT akaimasaya infliximabwasfoundtobeeffectivefortreatingimmunosuppressivedrugresistanthepatitisduetodurvalumab
AT ishizukatamotsu infliximabwasfoundtobeeffectivefortreatingimmunosuppressivedrugresistanthepatitisduetodurvalumab

Ejemplares similares